Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.62 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31306894 | 1.00 | SIRT6 (0.62) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL31377918 | 0.87 | P2RX7 (0.52) | SIRT6P2RX7MAOBKDM4EALDH1A1 | |
| SCHEMBL422747 | 0.80 | SIRT6 (0.57) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL16987317 | 0.79 | SIRT6 (0.52) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL18130913 | 0.79 | SIRT6 (0.52) | SIRT6JUNNFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL10708881 | 0.79 | MAOB (0.65) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL31041116 | 0.77 | SIRT6 (1.00) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL1432968 | 0.77 | SIRT6 (1.00) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL931449 | 0.77 | SIRT6 (0.49) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL10708728 | 0.77 | NPC1 (0.49) | SIRT6JUNNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854680-A | Isoxazole-heterocycle derivatives, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023185704-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | 上海赛默罗生物科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023010191-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007017752-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | SIRT6 3609/4885JUN 1833/4885NFKB1 2525/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | SIRT6 3743/4885JUN 3300/4885NFKB1 2066/4885 |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | SIRT6 348/4885JUN 1917/4885NFKB1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.